Tocilizumab in COVID-19 - Which Clinical Benefits?

Tocilizumab is a recombinant humanized monoclonal IL-6 receptor antibody indicated for the treatment of severe rheumatoid arthritis and other inflammatory disorders.Following clinical observation from China, a series of Italian studies have been carried out to evaluate the off-label use of tocilizumab in COVID-19 patients.
The European Journal of Internal Medicine (EJIM) has recently accepted for publication three articles on the off-label use of tocilizumab in patients with severe COVID-19.

FDIME Research Grant 2020

FDIME Announces Research Grants in 2020

The Foundation for the Development of Internal Medicine in Europe (FDIME) is offering Research Grants to Young Internists (up to age 38 yrs) to study in:
Research projects including all fields of General Internal Medicine, particularly polymorbidity and other common Internal Medicine conditions.

For details check the FDIME Research Grants webpage at www.fdime.org
OR

Download the Internal Medicine Grant Announcement and Application Form

For further information:

Choosing Wisely - COVID-19 Recommendations

The COVID-19 pandemic presents an unprecedented challenge to the capacity of health care systems and providers around the world. Now, more than ever, stewardship of limited resources is critical. 

In response, a list of nine recommendations for the public and clinicians was developed to raise awareness about the need to use limited health care resources wisely.

ESIM Summer 2020 - postponed to June 2021

In light of the latest developments of the COVID-19 pandemic and the current situation in Spain and all over Europe it has been decided to postpone the European Summer School of Internal Medicine, ESIM Summer 2020 to June 2021.

The school organisers together with the Spanish Society of Internal Medicine are working on confirming the new dates in June 2021. The School as officially communicated will take place in El Escorial, Madrid.

Further details will follow in the coming months.

Thank you for your understanding.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness